Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.
Cabio Biotech Wuhan Co Ltd (688089) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.034x
Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has a cash flow conversion efficiency ratio of 0.034x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.10 Million) by net assets (CN¥1.64 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cabio Biotech Wuhan Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cabio Biotech Wuhan Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei Mailyard Share Co Ltd
SHG:600107
|
0.009x |
|
Hunan Hansen Pharmaceutical Co Ltd
SHE:002412
|
0.023x |
|
Rainbow Tours SA
WAR:RBW
|
0.323x |
|
Hyliion Holdings Corp.
NYSE MKT:HYLN
|
-0.052x |
|
Fox-Wizel Ltd
PINK:FXWZF
|
0.112x |
|
TRANSILVANIA INVESTMENTS ALLIANCE S.A.
RO:TRANSI
|
N/A |
|
VIKRAM SOLAR LIMITED
NSE:VIKRAMSOLR
|
0.174x |
|
Texas Ventures Acquisition III Corp
NASDAQ:TVA
|
0.032x |
Annual Cash Flow Conversion Efficiency for Cabio Biotech Wuhan Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cabio Biotech Wuhan Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.57 Billion | CN¥173.04 Million | 0.110x | +139.09% |
| 2023-12-31 | CN¥1.49 Billion | CN¥68.89 Million | 0.046x | -62.75% |
| 2022-12-31 | CN¥1.43 Billion | CN¥176.40 Million | 0.124x | +65.60% |
| 2021-12-31 | CN¥1.38 Billion | CN¥103.29 Million | 0.075x | -32.18% |
| 2020-12-31 | CN¥1.32 Billion | CN¥145.88 Million | 0.110x | +4.38% |
| 2019-12-31 | CN¥1.25 Billion | CN¥131.95 Million | 0.106x | -47.66% |
| 2018-12-31 | CN¥526.20 Million | CN¥106.16 Million | 0.202x | -6.93% |
| 2017-12-31 | CN¥464.39 Million | CN¥100.66 Million | 0.217x | +39.56% |
| 2016-12-31 | CN¥402.60 Million | CN¥62.53 Million | 0.155x | +23.62% |
| 2015-12-31 | CN¥354.83 Million | CN¥44.58 Million | 0.126x | +26.32% |
| 2014-12-31 | CN¥465.90 Million | CN¥46.34 Million | 0.099x | +7.89% |
| 2013-12-31 | CN¥428.24 Million | CN¥39.48 Million | 0.092x | -- |